Cure of incurable lymphoma

Gerald L Denardo, Vladimir V. Sysko, Sally J. DeNardo

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

The most potent method for augmenting the cytocidal power of monoclonal antibody (MAb) treatment is to conjugate radionuclides to the MAb to deliver systemic radiotherapy (radioimmunotherapy; RIT). The antigen, MAb, and its epitope can make a difference in the performance of the drug. Additionally, the radionuclide, radiochemistry, chelator for radiometals and the linker between the MAb and chelator can have a major influence on the performance of drugs (radiopharmaceuticals) for RIT. Smaller radionuclide carriers, such as antibody fragments and mimics, and those used for pretargeting strategies, have been described and evaluated. All of these changes in the drugs and strategies for RIT have documented potential for improved performance and patient outcomes. RIT is a promising new therapy that should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after these patients have proven incurable. Predictable improvements using better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL, and likely lead to cure of currently incurable NHL.

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 1 2006

    Fingerprint

Keywords

  • Antibody
  • Lymphoma
  • Radioimmunotherapy
  • Radionuclide

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this